- Home
- UFG vs ZNTL Comparison
UFG vs ZNTL Comparison
Compare UFG & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFG
- ZNTL
- Stock Information
- Founded
- UFG 2021
- ZNTL 2014
- Country
- UFG Singapore
- ZNTL United States
- Employees
- UFG N/A
- ZNTL N/A
- Industry
- UFG Oil Refining/Marketing
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- UFG Energy
- ZNTL Health Care
- Exchange
- UFG Nasdaq
- ZNTL Nasdaq
- Market Cap
- UFG 136.4M
- ZNTL 137.9M
- IPO Year
- UFG 2025
- ZNTL 2020
- Fundamental
- Price
- UFG $5.52
- ZNTL $1.81
- Analyst Decision
- UFG
- ZNTL Buy
- Analyst Count
- UFG 0
- ZNTL 8
- Target Price
- UFG N/A
- ZNTL $8.53
- AVG Volume (30 Days)
- UFG 385.7K
- ZNTL 863.8K
- Earning Date
- UFG 01-01-0001
- ZNTL 03-26-2025
- Dividend Yield
- UFG N/A
- ZNTL N/A
- EPS Growth
- UFG N/A
- ZNTL N/A
- EPS
- UFG 0.02
- ZNTL N/A
- Revenue
- UFG $130,669,391.00
- ZNTL $67,425,000.00
- Revenue This Year
- UFG N/A
- ZNTL N/A
- Revenue Next Year
- UFG N/A
- ZNTL N/A
- P/E Ratio
- UFG $289.31
- ZNTL N/A
- Revenue Growth
- UFG 129.69
- ZNTL N/A
- 52 Week Low
- UFG $3.50
- ZNTL $1.61
- 52 Week High
- UFG $5.73
- ZNTL $16.27
- Technical
- Relative Strength Index (RSI)
- UFG N/A
- ZNTL 43.72
- Support Level
- UFG N/A
- ZNTL $1.78
- Resistance Level
- UFG N/A
- ZNTL $2.02
- Average True Range (ATR)
- UFG 0.00
- ZNTL 0.15
- MACD
- UFG 0.00
- ZNTL 0.01
- Stochastic Oscillator
- UFG 0.00
- ZNTL 38.81
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.